WaveMan
WaveMan · Company
TVGN · Tevogen Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TVGN Tevogen (TVGN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001860871
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
24
13F, latest reported quarter

Tevogen insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Tevogen Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Flomenberg Neal
See Remarks
SELL
2026-03-17 SECtraded 2026-03-13
501
$3.2K
+17.8%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 11, 2026.
  • The trade is 0.7% of the 76,940 shares held after it.
  • No other insider sold within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Flomenberg Neal sold about $3.2K of TVGN on Mar 13, 2026; 24 funds added in the latest 13F quarter.
Flomenberg Neal
See Remarks
SELL
2026-03-17 SECtraded 2026-03-11
452
$3.3K
+17.8%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 10, 2026.
  • The trade is 0.6% of the 77,441 shares held after it.
  • No other insider sold within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Flomenberg Neal sold about $3.3K of TVGN on Mar 11, 2026; 24 funds added in the latest 13F quarter.
Flomenberg Neal
See Remarks
SELL
2026-03-17 SECtraded 2026-03-10
19
$147
+17.8%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 12, 2025.
  • The trade is 0.0% of the 77,893 shares held after it.
  • No other insider sold within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Flomenberg Neal sold about $147 of TVGN on Mar 10, 2026; 24 funds added in the latest 13F quarter.
Saadi Ryan H.
Chief Executive Officer
SELL
2025-06-09 SEC
1,438,206
$1.8M
-89.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 5, 2024.
  • The trade is 1.2% of the 116,814,453 shares held after it.
  • No other insider sold within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Saadi Ryan H. sold about $1.8M of TVGN on Jun 9, 2025, the largest insider sale at the company on our record; 24 funds added in the latest 13F quarter.
Flomenberg Neal
See Remarks
SELL
2025-03-14 SECtraded 2025-03-12
232,968
$253.9K
-89.2%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 11, 2025.
  • The trade is 6.5% of the 3,595,608 shares held after it.
  • No other insider sold within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Flomenberg Neal sold about $253.9K of TVGN on Mar 12, 2025; 24 funds added in the latest 13F quarter.
15 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 10 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
24 funds bought in last quarter
below 65% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.6% of the float short (float per yahoo 2026-10-27) · 10.4 days to cover · settled 2026-10-15
below 74% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TVGN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-80.3%12M
-88%-57%-26%+5%2025-102025-122026-022026-042026-062026-082026-10 2026-03-11 · Flomenberg Neal sold $3.3K2026-03-13 · Flomenberg Neal sold $3.2K2026-03-10 · Flomenberg Neal sold $147
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TVGN: institutional holders (13F)

13F holdings, latest reported quarter
FourWorld Capital Management LLC
1,450,000 sh
$8.2M
BOOTHBAY FUND MANAGEMENT, LLC
25,000 sh
$141.5K
VANGUARD CAPITAL MANAGEMENT LLC
23,976 sh
$135.7K
MORGAN STANLEY
18,809 sh
$106.5K
AQR CAPITAL MANAGEMENT LLC
17,237 sh
$97.6K

Congress trades in TVGN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TVGN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 24 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TVGN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$11.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
no debt to cover
Return on equity
n/a
average equity is zero or negative
Return on assets
-480.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$40.9M
market value at close 2026-10-27 on 2026-08-10 shares, plus current debt only, 2022-12-31 (42 months older than the period end), minus cash 2025-12-31
FCF yield
-28.6%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$26.1M-$53.6M-$8.8Mn/a
Net income-$26.3M-$13.7M-$60.5M$4.4M
EPS (diluted)-8.08-3.50-2.44n/a
Operating cash flow-$12.3M-$12.0M-$8.2M-$215.4K
Cash$0$0$0$129.2K
Buybacksn/an/a$343.0Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

TVGN Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
35
Inputs
  • Funds adding, latest quarter24 · 35 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
51
Inputs
  • Short interest, % of float+6.6% · 51 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; no debt to cover
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies